Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus CLOXAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus CLOXAPEN.
AMPICILLIN TRIHYDRATE vs CLOXAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic